Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 147 points (1.0%) at 15,587 as of Thursday, Feb. 6, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,311 issues advancing vs. 626 declining with 152 unchanged. The Drugs industry currently sits up 0.8% versus the S&P 500, which is up 1.0%. Top gainers within the industry include Biogen Idec ( BIIB), up 1.9%, Shire ( SHPG), up 1.8%, Novo Nordisk A/S ( NVO), up 1.7%, GlaxoSmithKline ( GSK), up 0.9% and Johnson & Johnson ( JNJ), up 0.9%. TheStreet would like to highlight 5 stocks pushing the industry higher today: 5. Novartis ( NVS) is one of the companies pushing the Drugs industry higher today. As of noon trading, Novartis is up $0.88 (1.1%) to $79.43 on average volume. Thus far, 772,926 shares of Novartis exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $79.25-$79.61 after having opened the day at $79.55 as compared to the previous trading day's close of $78.55. Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Novartis has a market cap of $189.7 billion and is part of the health care sector. Shares are down 2.3% year-to-date as of the close of trading on Wednesday. Currently there are 4 analysts who rate Novartis a buy, no analysts rate it a sell, and 3 rate it a hold. TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Novartis Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.